Mythri Raghunandan

Mythri Raghunandan

Protocol Amendments – Causes, Impact and Strategies3 min read

Introduction

Protocol plays a central role in the efficient execution and completion of a clinical trial. Any change to the agreed protocol that affects the safety of subjects, scope and quality of study is considered unavoidable. These changes result in delays in Study timelines, lower patient retention rates, Site burdens, impending costs etc.. According to Tufts Center for the Study of Drug Development, the annual rate of procedures per protocol has increased from 6.5% to 8.7%, through the analysis of 57 Phase 2 and 3 protocols. This shows the increasing complexity of studies and consequent amendments to protocols.

The following are the key considerations and impact related to Protocol Amendments:

  1. Impact of Protocol Amendments
    1. Cost – The cost of an average of 3 amendments to phase I and 7 amendments to phase II and III ranges from $250,000 to $450,000 according to Tufts CSDD study. The major expense is IRB fees for any amendment to be approved. The review of the change in the protocol submitted to the authority incurs review charges.
    2. Time – Amendments do happen before even the patient is administered the first dose as per the protocol. The actual time taken to identify the problem with the existing protocol, the filing of the amendment and final implementation of the refined protocol took more than two months.
    3. Regulatory burden – CRO or Sponsor are bound to make unbudgeted expenses towards protocol amendment filing, review and approval from the regulatory authorities. Site burden increases with the implementation for every amendment. Procedures performed on subjects have to be performed again leading to poor retention rates.
  2. Factors leading to Protocol amendments
    1. Amendments occur in case of new Study dose information, variation in sample size, adverse events or serious adverse events, protocol design discrepancies, lower recruitment rates, changing regulatory demands all of these factors are responsible for changing the protocol. All of these factors are necessary to refine the protocol.
  3. Trends in Protocol implementation
    1. Master protocol studies –  Master protocols reduce the cycle time and generate quick real-world evidence related to the hypothesis tested. They also reduce the costs as the various stakeholders involved can share the trial costs. Quantum Leap Healthcare Collaborative™ (QLHC) study “I SPY 2” is an ongoing Platform trial started in 2010 testing multiple therapies for Breast cancer and has recruited more than 1300 patients and has evaluated 12 drugs by 2018. There is an increase in the adoption of Master protocols as they are patient-focused and give out results much earlier compared to traditional designs.
    2. Evidence-based protocols – The evidence-based protocols are proven to minimize the costs, patient stay and study failure rates. There is a paradigm shift towards designing the protocol based on real-world health data analysis. For example, Health device data is used to create digital biomarkers via eTools capturing EHR/EMR data providing simplified protocols ,in turn, reducing amendments.
  4. Industry strategies to tackle amendments.
    1. The Industry should typically plan and budget upfront for two amendments for every clinical trial so that the appropriate costs and timeline impact is accounted for without any surprises.
    2. Ensure proper continuous communication with the Sites as the protocol evolves in the study.
    3. Improving the protocol authoring practices and internal feasibility assessments will lead to reduced protocol amendments.
    4. The Clinical trial design process is evaluated along with predictive analytics, local expertise to come out with simple protocols less prone to amendments.
    5. Leverage technology solutions that capture the real-time amendment status, frequency, version and automated approval of protocol amendments.

References

https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5aa2bccc9140b7f28066f810

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053871/

https://journals.sagepub.com/doi/abs/10.1177/009286151104500307

https://www.nejm.org/doi/full/10.1056/NEJMra1510062?sort=oldest&page=-6

https://apps.who.int/iris/bitstream/handle/10665/260421/WHO-NMH-NVI-18.2-eng.pdf;jsessionid=1E1CB812E6DB70DFAC55380AFE1D2DF8?sequence=1

https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting-protocol-amendments

https://www.pharmoutsourcing.com/Featured-Articles/333834-Diagnosing-Protocol-Amendment-Experience-to-Drive-Clinical-Trial-Performance/

SHARE THIS POST

LinkedIn
Twitter
Facebook

Related Blog​s

CTMS
Abhijit Joshi

Clinical Trials of the Future

The clinical research industry has been rapidly remodeled by the digital revolution.

This paradigm shift is exploding into a new way of drug development and clinical trials. A way where patient experience is at utmost precedence.

Revolving business models, services, and products around the patient is becoming the new normal.

Read More »
CTMS
Srinivas Sashidhar K

5 Things to Consider to Choose the Right CTMS

A number of solutions are being built to manage day-to-day clinical trial activities. Most solution providers in the market claim to have a complete CTMS solution, however, not all solutions have end-to-end features. A checklist for systematic assessment of the available CTMS solutions prior to investment is essential.
Most importantly, CTMS will be used to manage sensitive medical data

Read More »
Clinical Research
Abhijit Joshi

Enabling Your Remote Workforce

We thought of changing it up this week to share how our team is working with our customers during these unprecedented times.

With today’s capricious working culture, here are some practices we are implementing with our loyal customers:

Read More »

©2020 Cloudbyz Inc. All Rights Reserved.